Revenue segments as reported by the company.

Product sales

Other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Acquired in-process research and development

Selling, general and administrative

Other

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Amgen

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, Aimovig, KANJINTI, EVENITY, AMGEVITA, AVSOLA, BLINCYTO, MVASI, Corlanor, Enbrel, EPOGEN, IMLYGIC, Kyprolis, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, Otezla, RIABNI, and XGEVA. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Amgen reports robust Q4 results, navigates pricing challenges for growth

Amgen's Q4 earnings call highlighted strong performance, innovative products, and strategic acquisitions driving growth. Challenges in pricing strategies and market dynamics require careful navigation. Opportunities in promising data, asset advancements, and access strategies position Amgen for future success.

Amgen reports robust Q1 performance, eyes growth in Asia-Pacific

Amgen's Q1 2023 earnings call highlighted strong performance, innovative R&D focus, and growth in key markets like Asia-Pacific.
Despite challenges with inventory issues and pricing dynamics, the company remains optimistic about long-term growth opportunities and biosimilar competitiveness.
Opportunities lie in addressing complex disorders like obesity, expanding market presence, and driving growth in key product franchises.
Overall, Amgen's strategic focus on performance, international expansion, and pipeline advancements positions the company for sustained growth and innovation.

Amgen reports robust Q2 earnings, eyes growth through strategic acquisitions

Amgen's strong Q2 performance, robust sales growth, and strategic acquisitions position the company for continued success.
While facing challenges in competitive markets and potential legal risks, Amgen's focus on innovation and portfolio expansion presents growth opportunities.
With a solid financial outlook, increased R&D investments, and a focus on shareholder returns, Amgen remains well-positioned for future growth.
Updates on key products, positive trial results, and strategic initiatives underscore Amgen's commitment to advancing healthcare and driving value creation.

Amgen reports revenue and earnings growth, eyes AI for innovation

Amgen's Q3 performance showed revenue and earnings growth, driven by strong global volume and record sales for key medicines. The company's pipeline progress and strategic focus on R&D highlight a commitment to innovation and future growth. While challenges exist around acquisition integration and market competition, Amgen is poised for continued success through the end of the decade and beyond.

Amgen reports record sales in Q4 2023, eyes rare diseases

Amgen's Q4 2023 performance was robust, driven by record sales and strategic acquisitions.
Despite short-term challenges like tax payments impacting cash flow, the company remains confident in its long-term growth trajectory.
Opportunities lie in expanding the rare disease portfolio, advancing R&D initiatives, and exploring new therapeutic areas.
Overall, Amgen's strong financials, diverse pipeline, and focus on innovation position it well for sustained growth and global impact.

Amgen reports strong Q1 growth, eyes new markets and innovations

Amgen's Q1 2024 performance reflects strong sales growth, financial resilience, and continued momentum in key product segments, positioning the company for future success.
Despite challenges in competitive differentiation, product launches, and regulatory complexities, Amgen's strategic strengths in innovation, manufacturing, and market expansion offer a solid foundation for growth.
The company's focus on addressing unmet medical needs, exploring new therapeutic areas, and advancing pipeline candidates underscores its commitment to driving patient impact and capturing market opportunities.
With a robust financial outlook, ongoing Phase III trials, and a proactive approach to product development, Amgen is well-positioned to achieve its revenue targets, drive innovation, and deliver value to shareholders.

Amgen reports strong Q2 earnings, eyes growth in diverse markets

Amgen's Q2 2024 earnings call highlighted robust revenue growth, strong sales performance, and promising pipeline developments across various therapeutic areas.
While facing challenges in market dynamics and product differentiation, Amgen's strategic focus on rare diseases and innovative therapies positions it well for future growth.
With a clear outlook on capital allocation, continued expansion in endocrinology, and opportunities in the obesity market, Amgen remains poised for sustained success.

Amgen reports strong Q3 earnings and outlines growth strategies

Amgen's Q3 2024 earnings call highlighted robust financial performance, progress in pipeline development, and strategic initiatives for future growth. With a strong revenue outlook and focus on innovation, Amgen remains well-positioned in the biopharmaceutical industry.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. It operates through Human Therapeutics segment. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Amgen is a biotech company with a strong track record of returning capital to shareholders and maintaining high profitability. The company has outperformed the S&P 500 and other pharmaceutical peers in terms of total returns over the past decade. It has a robust pipeline of drugs and, unlike some peers, is reasonably valued with a respectable and well-covered dividend.

Amgen: Wonderful Stock At Decent Price

Amgen Inc. is a biotech company known for its innovative therapies and focus on areas with significant unmet medical needs. The company showcases strong financial health, with a past quarter of increased YoY revenues and earnings per share. The Inflation Reduction Act is likely to negatively impact a handful of pharmaceutical companies, including Amgen, and therefore subject to inflationary penalties.

Amgen: Bet On Its Breakthrough Drug

AbbVie

Colgate-Palmolive

Con Ed

Hershey

Coca-Cola

Philip Morris

Colgate-Palmolive, Amgen, and others have solid records of increasing dividend payments.

7 Dividend Stocks to Buy as Bond Yields Fall

Cisco Systems

Chevron

Dow Inc

Johnson & Johnson

Verizon

Walgreens

Don't look now. But dividends are back in vogue.

The Dogs of the Dow May Pay Big Dividends in 2024

Amgen's (AMGN) BLA for tarlatamab to treat advanced small cell lung cancer gets FDA's priority review. A decision is expected on Jun 12, 2024.

Amgen's (AMGN) Tarlatamab BLA Gets FDA Priority Tag for SCLC

James Bradner, M.D., Joins as Executive Vice President, Research and Development, and Chief Scientific Officer  David M.

AMGEN ANNOUNCES EXECUTIVE APPOINTMENTS TO ACCELERATE INNOVATION

Sponsorship of the Golf Event Continues Following Horizon Acquisition Golfers Shane Lowry, Pádraig Harrington, Séamus Power and Brendan Lawlor Will Become Amgen Golf Ambassadors THOUSAND OAKS, Calif. , Dec. 14, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced it will serve as the title sponsor of the Irish Open starting in 2024, following the acquisition of Horizon Therapeutics plc in October 2023.

AMGEN TO SPONSOR THE IRISH OPEN

Currently There are no Approved Therapeutic Options for Third-Line Treatment of Advanced SCLC1 If Approved, Tarlatamab Would be the First BiTE® Therapy for a Major Solid Tumor FDA Target Action Date is June 12, 2024 THOUSAND OAKS, Calif. , Dec. 13, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review for the Company's Biologics License Application (BLA) for tarlatamab.

FDA Grants Priority Review to Amgen's Tarlatamab Application for Advanced Small Cell Lung Cancer

Amgen Inc. AMGN, +0.68% said late Tuesday its board has authorized a dividend of $2.25 a share, up from $2.13 a share. That's the 12th straight year that Amgen has increased its dividend, the company said.

Amgen raises dividend to $2.25 a share

THOUSAND OAKS, Calif. , Dec. 12, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.25 per share dividend for the first quarter of 2024.

AMGEN ANNOUNCES 2024 FIRST QUARTER DIVIDEND INCREASE TO $2.25 PER SHARE

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Here's Why Amgen (AMGN) is a Strong Value Stock

AstraZeneca

Bristol-Myers

Gilead Sciences

Merck

Novo Nordisk

Novartis

Pfizer

Sanofi

This biotech giant remains a top stock for investors to buy and pays a solid 3.13% dividend.

6 Health Care Dividend Stocks To By Hand Over Fist

Multiple Investigator Sponsored Studies Support the Potential of BLINCYTO®  (blinatumomab) Across Acute Lymphoblastic Leukemia Treatment Paradigm New Data Reinforce KYPROLIS® (carfilzomib) as an Important Treatment Option for Relapsed or Refractory Multiple Myeloma Additional Analyses Support Eculizumab (a biosimilar candidate to SOLIRIS®) as a Potential Option in Paroxysmal Nocturnal Hemoglobinuria THOUSAND OAKS, Calif. , Dec. 8, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the presentation of new data from its blood cancer portfolio and pipeline at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, taking place from Dec. 9-12 in San Diego.

AMGEN HIGHLIGHTS HEMATOLOGY PORTFOLIO AT ASH 2023

In the latest trading session, Amgen (AMGN) closed at $269.35, marking a -0.56% move from the previous day.

Amgen (AMGN) Registers a Bigger Fall Than the Market: Important Facts to Note

Broadcom

Mastercard

Stryker

Zoetis

The company offers integrated products and value-added services for Account holders Merchants Financial institutions Businesses Governments Mastercard also provides value-added products and services comprising cyber and intelligence solutions for parties to transact and proprietary insights, drawing on the moral use of consumer and merchant data services.

5 Sizzling Wall Street ‘Strong Buy” Stocks Are Also Raising Their Dividends This Week

Goldman Sachs

Walmart

"The Dow [adds a stock] if the company has an excellent reputation, demonstrates sustained growth, and is of interest to a large number of investors. Sector representation is also a consideration.” – Dow Jones & Co. The highest-yield 10 stocks are December's Dogs of the Dow: KO, AMGN, CSCO, GS, IBM, CVX, DOW, MMM, VZ, and WBA. They only averaged a 4.92% annual yield, as December prices rose. Thirty Dow stocks represent nine of eleven sectors. Dow Jones tracks utilities as a separate index and omits real estate. Broker top-ten target-estimated December net gains ranged between 11.08%-44.04%, topped by WBA 11/30/23.

December Dogs Of The Dow: 3 Buyable, 5 Watchable

Archer-Daniels-Midland Company

Automatic Data Processing

American Electric Power Company

Atmos Energy

Auburn National Bancorporation

Avnet

Avery Dennison

Best Buy

Becton, Dickinson and Co.

Blackrock Inc

Badger Meter

Bank of Montreal

Cabot

Cogent Communications Holdings

Canadian Imperial Bank of Commerce

CME Group

Canadian National Railway Company

CNO Financial Group

ChoiceOne Financial Services Inc

CRA International

Discover

Dolby Laboratories

A weekly summary of dividend activity for Dividend Champions, Contenders, and Challengers. Companies which changed their dividends. Companies with upcoming ex-dividend dates.

Dividend Champion, Contender, And Challenger Highlights: Week Of December 3

Amgen (AMGN) reported earnings 30 days ago. What's next for the stock?

Amgen (AMGN) Up 2.2% Since Last Earnings Report: Can It Continue?

Amgen Inc. (NASDAQ:AMGN ) 6th Annual Evercore ISI HealthCONx Conference November 29, 2023 9:10 AM ET Company Participants Peter Griffith - EVP and CFO Paul Burton - Chief Medical Officer Justin Claeys - VP, IR Conference Call Participants Umer Raffat - Evercore ISI Umer Raffat It's pleasure to have Amgen management with us today. I feel like between Sean [ph] and myself covering Amgen for, like, 14 years now, I have not seen this type of setup come up in terms of pipeline readouts for Amgen, in a long time.

Amgen Inc. (AMGN) Presents at 6th Annual Evercore ISI HealthCONx Conference (Transcript)

Agilent Technologies

Apple

Accenture Plc

Amazon

Air Products and Chemicals

Ares Capital

Alexandria Real Estate Equities

ASML Hld

AvalonBay Communities

Booz Allen Hamilton Hld

I've made significant changes to my portfolio due to buying a new house and selling stocks from my portfolio to raise cash. My goal is to prioritize building a passive income stream, but I recognize the value of investing in a new home for improved quality of life. In this article, I discuss different options to pay for the new home, including taking out a mortgage or selling more stock if mortgage rates remain high.

Why I Made Big Changes To My Dividend Growth Portfolio

News for Amgen Stock (AMGN)